Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetics (PK), safety, and tolerability of a single
intravenous (IV) dose of rezafungin in paediatric subjects from birth to <18 years who are
receiving concomitant systemic antifungals as clinically indicated.